Which has preferable valuation & earnings, KARD or ERAS?

Erasca is trading at a lower price-to-earnings ratio than Kardigan, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kardigan N/A N/A -$191.94M -$2.88 N/A Erasca N/A N/A -$124.55M -$0.95 N/A

Is KARD or ERAS more profitable?

Kardigan's return on equity of 0.00% beat Erasca's return on equity. Company Net Margins Return on Equity Return on Assets Kardigan N/A N/A N/A Erasca N/A -38.43% -32.05%

Does the media favor KARD or ERAS?

In the previous week, Erasca had 1 more articles in the media than Kardigan. MarketBeat recorded 5 mentions for Erasca and 4 mentions for Kardigan. Erasca's average media sentiment score of 0.58 beat Kardigan's score of 0.04 indicating that Erasca is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kardigan 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Erasca 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, KARD or GRFS?

Grifols has higher revenue and earnings than Kardigan. Kardigan is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Kardigan N/A N/A -$191.94M -$2.88 N/A Grifols $8.51B 0.60 $454.82M $0.19 39.58

Is KARD or GRFS more profitable?

Grifols has a net margin of 5.54% compared to Kardigan's net margin of 0.00%. Grifols' return on equity of 6.21% beat Kardigan's return on equity. Company Net Margins Return on Equity Return on Assets Kardigan N/A N/A N/A Grifols 5.54% 6.21% 2.39%

Does the media prefer KARD or GRFS?

In the previous week, Kardigan had 3 more articles in the media than Grifols. MarketBeat recorded 4 mentions for Kardigan and 1 mentions for Grifols. Grifols' average media sentiment score of 0.95 beat Kardigan's score of 0.04 indicating that Grifols is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kardigan 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Grifols 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor DNTH or KARD?

In the previous week, Kardigan had 3 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 4 mentions for Kardigan and 1 mentions for Dianthus Therapeutics. Dianthus Therapeutics' average media sentiment score of 0.15 beat Kardigan's score of 0.04 indicating that Dianthus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kardigan 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, EWTX or KARD?

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Kardigan, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Edgewise Therapeutics N/A N/A -$167.79M -$1.85 N/A Kardigan N/A N/A -$191.94M -$2.88 N/A

Is EWTX or KARD more profitable?

Kardigan's return on equity of 0.00% beat Edgewise Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Edgewise Therapeutics N/A -39.01% -36.96% Kardigan N/A N/A N/A

Does the media prefer EWTX or KARD?

In the previous week, Edgewise Therapeutics had 1 more articles in the media than Kardigan. MarketBeat recorded 5 mentions for Edgewise Therapeutics and 4 mentions for Kardigan. Edgewise Therapeutics' average media sentiment score of 0.51 beat Kardigan's score of 0.04 indicating that Edgewise Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kardigan 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor KARD or ABCL?

In the previous week, AbCellera Biologics had 2 more articles in the media than Kardigan. MarketBeat recorded 6 mentions for AbCellera Biologics and 4 mentions for Kardigan. AbCellera Biologics' average media sentiment score of 0.11 beat Kardigan's score of 0.04 indicating that AbCellera Biologics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kardigan 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral AbCellera Biologics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Kardigan (KARD) Competitors

$13.83 +0.34 (+2.52%)

As of 04:00 PM Eastern

Compare

KARD vs. ERAS, GRFS, DNTH, EWTX, and ABCL

Should you buy Kardigan stock or one of its competitors? Kardigan's main competitors and comparable companies include Erasca (ERAS), Grifols (GRFS), Dianthus Therapeutics (DNTH), Edgewise Therapeutics (EWTX), and AbCellera Biologics (ABCL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Kardigan compare to Erasca?

Kardigan (NASDAQ:KARD) and Erasca (NASDAQ:ERAS) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation.

67.8% of Erasca shares are owned by institutional investors. 14.2% of Erasca shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Kardigan's return on equity of 0.00% beat Erasca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kardigan	N/A	N/A	N/A
Erasca	N/A	-38.43%	-32.05%

Kardigan presently has a consensus price target of $42.25, indicating a potential upside of 213.19%. Erasca has a consensus price target of $22.09, indicating a potential upside of 54.48%. Given Kardigan's higher probable upside, equities research analysts clearly believe Kardigan is more favorable than Erasca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kardigan	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Erasca	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

In the previous week, Erasca had 1 more articles in the media than Kardigan. MarketBeat recorded 5 mentions for Erasca and 4 mentions for Kardigan. Erasca's average media sentiment score of 0.58 beat Kardigan's score of 0.04 indicating that Erasca is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kardigan	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Erasca	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Erasca is trading at a lower price-to-earnings ratio than Kardigan, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kardigan	N/A	N/A	-$191.94M	-$2.88	N/A
Erasca	N/A	N/A	-$124.55M	-$0.95	N/A

Summary

Erasca beats Kardigan on 8 of the 12 factors compared between the two stocks.

How does Kardigan compare to Grifols?

Kardigan (NASDAQ:KARD) and Grifols (NASDAQ:GRFS) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk.

Grifols has a net margin of 5.54% compared to Kardigan's net margin of 0.00%. Grifols' return on equity of 6.21% beat Kardigan's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kardigan	N/A	N/A	N/A
Grifols	5.54%	6.21%	2.39%

Grifols has higher revenue and earnings than Kardigan. Kardigan is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kardigan	N/A	N/A	-$191.94M	-$2.88	N/A
Grifols	$8.51B	0.60	$454.82M	$0.19	39.58

In the previous week, Kardigan had 3 more articles in the media than Grifols. MarketBeat recorded 4 mentions for Kardigan and 1 mentions for Grifols. Grifols' average media sentiment score of 0.95 beat Kardigan's score of 0.04 indicating that Grifols is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kardigan	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Grifols	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Kardigan presently has a consensus target price of $42.25, suggesting a potential upside of 213.19%. Grifols has a consensus target price of $10.00, suggesting a potential upside of 32.98%. Given Kardigan's stronger consensus rating and higher possible upside, analysts plainly believe Kardigan is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kardigan	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Grifols	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

Grifols beats Kardigan on 8 of the 12 factors compared between the two stocks.

How does Kardigan compare to Dianthus Therapeutics?

Dianthus Therapeutics (NASDAQ:DNTH) and Kardigan (NASDAQ:KARD) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership.

In the previous week, Kardigan had 3 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 4 mentions for Kardigan and 1 mentions for Dianthus Therapeutics. Dianthus Therapeutics' average media sentiment score of 0.15 beat Kardigan's score of 0.04 indicating that Dianthus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dianthus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kardigan	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

47.5% of Dianthus Therapeutics shares are owned by institutional investors. 3.0% of Dianthus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Dianthus Therapeutics has higher revenue and earnings than Kardigan. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than Kardigan, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dianthus Therapeutics	$2.04M	2,294.08	-$162.34M	-$4.15	N/A
Kardigan	N/A	N/A	-$191.94M	-$2.88	N/A

Dianthus Therapeutics currently has a consensus target price of $129.83, suggesting a potential upside of 52.03%. Kardigan has a consensus target price of $42.25, suggesting a potential upside of 213.19%. Given Kardigan's higher possible upside, analysts clearly believe Kardigan is more favorable than Dianthus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dianthus Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Kardigan	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Kardigan has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -10,096.95%. Kardigan's return on equity of 0.00% beat Dianthus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dianthus Therapeutics	-10,096.95%	-22.53%	-21.55%
Kardigan	N/A	N/A	N/A

Summary

Dianthus Therapeutics beats Kardigan on 8 of the 15 factors compared between the two stocks.

How does Kardigan compare to Edgewise Therapeutics?

Edgewise Therapeutics (NASDAQ:EWTX) and Kardigan (NASDAQ:KARD) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk, analyst recommendations and media sentiment.

In the previous week, Edgewise Therapeutics had 1 more articles in the media than Kardigan. MarketBeat recorded 5 mentions for Edgewise Therapeutics and 4 mentions for Kardigan. Edgewise Therapeutics' average media sentiment score of 0.51 beat Kardigan's score of 0.04 indicating that Edgewise Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kardigan	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Kardigan, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.85	N/A
Kardigan	N/A	N/A	-$191.94M	-$2.88	N/A

Edgewise Therapeutics currently has a consensus price target of $51.33, suggesting a potential upside of 28.27%. Kardigan has a consensus price target of $42.25, suggesting a potential upside of 213.19%. Given Kardigan's higher possible upside, analysts clearly believe Kardigan is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Kardigan	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Kardigan's return on equity of 0.00% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-39.01%	-36.96%
Kardigan	N/A	N/A	N/A

Summary

Edgewise Therapeutics beats Kardigan on 7 of the 11 factors compared between the two stocks.

How does Kardigan compare to AbCellera Biologics?

Kardigan (NASDAQ:KARD) and AbCellera Biologics (NASDAQ:ABCL) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment.

Kardigan currently has a consensus target price of $42.25, suggesting a potential upside of 213.19%. AbCellera Biologics has a consensus target price of $13.38, suggesting a potential upside of 1.71%. Given Kardigan's higher possible upside, equities research analysts clearly believe Kardigan is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kardigan	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
AbCellera Biologics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67

AbCellera Biologics has higher revenue and earnings than Kardigan. AbCellera Biologics is trading at a lower price-to-earnings ratio than Kardigan, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kardigan	N/A	N/A	-$191.94M	-$2.88	N/A
AbCellera Biologics	$75.13M	53.67	-$146.41M	-$0.54	N/A

Kardigan has a net margin of 0.00% compared to AbCellera Biologics' net margin of -248.83%. Kardigan's return on equity of 0.00% beat AbCellera Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kardigan	N/A	N/A	N/A
AbCellera Biologics	-248.83%	-17.49%	-12.36%

61.4% of AbCellera Biologics shares are owned by institutional investors. 28.4% of AbCellera Biologics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, AbCellera Biologics had 2 more articles in the media than Kardigan. MarketBeat recorded 6 mentions for AbCellera Biologics and 4 mentions for Kardigan. AbCellera Biologics' average media sentiment score of 0.11 beat Kardigan's score of 0.04 indicating that AbCellera Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kardigan	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
AbCellera Biologics	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

AbCellera Biologics beats Kardigan on 10 of the 15 factors compared between the two stocks.

Get Kardigan News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KARD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KARD vs. The Competition

Export

Metric	Kardigan	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.29B	$3.85B	$7.19B	$13.38B
Dividend Yield	N/A	3.65%	2.53%	17.39%
P/E Ratio	-4.80	13.60	275.11	26.15
Price / Sales	N/A	1,231.10	634.19	106.70
Price / Cash	N/A	126.56	79.41	53.24
Price / Book	N/A	15.98	10.74	6.27
Net Income	-$191.94M	-$22.65M	$3.50B	$382.03M
7 Day Performance	-6.24%	-4.52%	-1.55%	-0.85%
1 Month Performance	-33.67%	-12.53%	-6.73%	-5.29%
1 Year Performance	N/A	13.36%	5.67%	0.73%

Kardigan Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KARD Kardigan	3.1416 of 5 stars	$13.83 +2.5%	$42.25 +205.5%	N/A	$1.29B	N/A	N/A	241
ERAS Erasca	2.3487 of 5 stars	$14.74 +1.1%	$22.09 +49.9%	+513.7%	$5.10B	N/A	N/A	103
GRFS Grifols	4.5336 of 5 stars	$7.31 +0.1%	$10.00 +36.8%	-21.7%	$4.97B	$8.51B	38.47	25,247
DNTH Dianthus Therapeutics	2.0394 of 5 stars	$88.21 -0.1%	$129.83 +47.2%	+147.8%	$4.84B	$1.90M	N/A	92
EWTX Edgewise Therapeutics	2.6941 of 5 stars	$41.40 +2.3%	$51.33 +24.0%	+160.7%	$4.40B	N/A	N/A	127	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KARD) was last updated on 10/7/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Kardigan (KARD) Competitors

KARD vs. ERAS, GRFS, DNTH, EWTX, and ABCL

How does Kardigan compare to Erasca?

Summary

How does Kardigan compare to Grifols?

Summary

How does Kardigan compare to Dianthus Therapeutics?

Summary

How does Kardigan compare to Edgewise Therapeutics?

Summary

How does Kardigan compare to AbCellera Biologics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KARD vs. The Competition

Kardigan Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Kardigan (KARD) Competitors

KARD vs. ERAS, GRFS, DNTH, EWTX, and ABCL

How does Kardigan compare to Erasca?

Do insiders & institutionals have more ownership in KARD or ERAS?

Is KARD or ERAS more profitable?

Do analysts prefer KARD or ERAS?

Does the media favor KARD or ERAS?

Which has preferable valuation & earnings, KARD or ERAS?

Summary

How does Kardigan compare to Grifols?

Is KARD or GRFS more profitable?

Which has better earnings & valuation, KARD or GRFS?

Does the media prefer KARD or GRFS?

Do analysts rate KARD or GRFS?

Summary

How does Kardigan compare to Dianthus Therapeutics?

Does the media favor DNTH or KARD?

Do insiders & institutionals hold more shares of DNTH or KARD?

Which has better valuation and earnings, DNTH or KARD?

Do analysts recommend DNTH or KARD?

Is DNTH or KARD more profitable?

Summary

How does Kardigan compare to Edgewise Therapeutics?

Does the media prefer EWTX or KARD?

Which has better earnings & valuation, EWTX or KARD?

Do analysts recommend EWTX or KARD?

Is EWTX or KARD more profitable?

Summary

How does Kardigan compare to AbCellera Biologics?

Do analysts rate KARD or ABCL?

Which has better earnings and valuation, KARD or ABCL?

Is KARD or ABCL more profitable?

Do insiders & institutionals have more ownership in KARD or ABCL?

Does the media favor KARD or ABCL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KARD vs. The Competition

Kardigan Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools